Challenging Cases: HPI Switching in BCC, Adjuvant Therapy in CSCC

Program Overview

As immunotherapy gains momentum in the treatment of nonmelanoma skin cancer, clinicians may be challenged by questions regarding optimal timing and integration in patient care. In this program, experts provide privileged insights into real-world cases submitted by dermatologists and oncologists.

Credit Expired

Target Audience

This educational activity is designed to meet the needs of medical oncology physicians, dermatology physicians, and other clinicians involved in the management of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Integrate immunotherapy in the management of patients with advanced basal cell carcinoma (BCC) based on the latest clinical trial data
  • Select appropriate immunotherapy for advanced cutaneous squamous cell carcinoma (CSCC) based on current safety and efficacy data

Activity Faculty

Lewis 2021

Karl D. Lewis, MD

Professor, Medicine
Division of Medical Oncology
Cutaneous Oncology Program
University of Colorado
Aurora, CO

Ahmad TarhiniDO NOT EDIT

Ahmad Tarhini, MD, PhD

Senior Member, Cutaneous Oncology and Immunology
Director, Cutaneous Clinical and Translational Research
H. Lee Moffitt Cancer Center and Research Institute
Professor, Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources